| Bioactivity | Hepln-13 is a potent and orally active Hepsin inhibitor with an IC50 of 0.33 µM. Hepln-13 can be used for the research of metastatic prostate cancer[1]. |
| Target | IC50: 0.33 μM (Hepsin) |
| Invitro | Hepln-13 (10 µM; 2 hours; 293 cells) inhibits cleavage[1]. Western Blot Analysis[1] Cell Line: |
| In Vivo | HepIn-13 displays dose dependent inhibition of Hepsin overexpression-relevant prostate cancer phenotypes and blocks prostate cancer metastasis[1]. |
| Name | Hepln-13 |
| CAS | 64369-13-7 |
| Formula | C17H13BrN2 |
| Molar Mass | 325.20 |
| Appearance | Solid |
| Transport | Room temperature in continental US; may vary elsewhere. |
| Storage | 4°C, protect from light *In solvent : -80°C, 6 months; -20°C, 1 month (protect from light) |
| Reference | [1]. Tang X, et al. Targeted inhibition of cell-surface serine protease Hepsin blocks prostate cancer bone metastasis. Oncotarget. 2014;5(5):1352-1362. |